Zhejiang Hisoar Pharmaceutical Management
Management criteria checks 2/4
Zhejiang Hisoar Pharmaceutical's CEO is Guorui Xu, appointed in Nov 2014, has a tenure of 10.08 years. directly owns 0.028% of the company’s shares, worth CN¥2.40M. The average tenure of the management team and the board of directors is 10.1 years and 2.5 years respectively.
Key information
Guorui Xu
Chief executive officer
CN¥1.0m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 10.1yrs |
| CEO ownership | 0.03% |
| Management average tenure | 10.1yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Price Is Out Of Tune With Revenues
Sep 27
Does Zhejiang Hisoar Pharmaceutical (SZSE:002099) Have A Healthy Balance Sheet?
Aug 30Zhejiang Hisoar Pharmaceutical (SZSE:002099) Has Debt But No Earnings; Should You Worry?
May 27Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) Shares Climb 28% But Its Business Is Yet to Catch Up
Mar 03CEO
Guorui Xu (47 yo)
10.1yrs
Tenure
CN¥1,000,600
Compensation
Mr. Guorui Xu serves as Non-Independent Director at Zhejiang Hisoar Pharmaceutical Co., Ltd. since November 30, 2022 and serves as its General Manager. He had been Deputy General Manager at Zhejiang Hisoar...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 10.1yrs | CN¥1.00m | 0.028% CN¥ 2.4m | |
| Vice President | 1.2yrs | CN¥1.00m | no data | |
| Deputy General Manager | 11.4yrs | CN¥600.80k | 0.085% CN¥ 7.2m | |
| Accounting Supervisor | no data | no data | no data | |
| Vice President | no data | CN¥350.70k | no data |
10.1yrs
Average Tenure
47yo
Average Age
Experienced Management: 002099's management team is seasoned and experienced (10.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Director | 2.1yrs | CN¥1.00m | 0.028% CN¥ 2.4m | |
| Vice President | 5.1yrs | CN¥1.00m | no data | |
| Member of the Supervisory Board | 12.2yrs | no data | no data | |
| Chairman | 5.1yrs | CN¥608.00k | 0.13% CN¥ 10.9m | |
| Employees Representative Chairman of Supervisory Board | 5.1yrs | no data | no data | |
| Non-Employee Supervisor | 2.9yrs | no data | no data | |
| Non-Independent Director | 2.1yrs | CN¥48.30k | no data | |
| Independent Director | 2.1yrs | CN¥80.00k | no data | |
| Independent Director | 2.1yrs | CN¥6.70k | no data | |
| Independent Director | 2.1yrs | CN¥6.70k | no data |
2.5yrs
Average Tenure
51yo
Average Age
Experienced Board: 002099's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 19:09 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Hisoar Pharmaceutical Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peng Yan | Changjiang Securities Co. LTD. |
| Liang Sun | China International Capital Corporation Limited |
| Jie Yao | Everbright Securities Co. Ltd. |